Swedish Orphan Biovitrum Sustainability Profile
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a leading biopharmaceutical company headquartered in Sweden (SE). Founded in 1991, Sobi has established itself as a key player in the biotechnology industry, focusing on rare diseases and specialty care. With a strong operational presence across Europe, North America, and the Asia-Pacific region, Sobi is dedicated to developing innovative therapies that address unmet medical needs. Sobi's core product portfolio includes treatments for haemophilia, inflammation, and genetic disorders, distinguished by their commitment to patient-centric solutions and advanced biopharmaceutical technologies. The company has achieved significant milestones, including strategic partnerships and a robust pipeline of therapies, solidifying its market position as a trusted provider in the rare disease sector. Sobi continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by complex health conditions.
DitchCarbon Score
How does Swedish Orphan Biovitrum's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Swedish Orphan Biovitrum's score of 54 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Swedish Orphan Biovitrum's reported carbon emissions
In 2024, Swedish Orphan Biovitrum AB (Sobi) reported total carbon emissions of approximately 253,324,000 kg CO2e. This includes 1,097,000 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 771,000 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity, heat, and cooling. The majority of Sobi's emissions, about 251,456,000 kg CO2e, fall under Scope 3, which includes emissions from the entire value chain, such as purchased goods and services. In 2023, Sobi's total emissions were approximately 194,977,000 kg CO2e, with Scope 1 emissions at 1,053,000 kg CO2e and Scope 2 emissions at 815,000 kg CO2e. This indicates a significant increase in emissions from 2023 to 2024. Sobi has set ambitious climate commitments, aiming for a 37.8% absolute reduction in combined Scope 1 and 2 emissions by 2029, using 2023 as the base year. Additionally, the company is committed to ensuring that 65% of its suppliers, by spend, will have science-based targets by the same year. Sobi also aims to achieve net-zero emissions for its operational GHG footprint in both Scope 1 and Scope 2 by 2030. These targets align with the Science Based Targets initiative (SBTi) and reflect Sobi's commitment to reducing its environmental impact in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 435,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,157,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | 000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Swedish Orphan Biovitrum's Industry?
How Carbon Intensive is Swedish Orphan Biovitrum's Location?
Swedish Orphan Biovitrum's Scope 3 Categories Breakdown
Swedish Orphan Biovitrum's Scope 3 emissions, which increased by 30% last year and increased significantly since 2017, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 86% of Scope 3 emissions.
Top Scope 3 Categories
Swedish Orphan Biovitrum's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Swedish Orphan Biovitrum has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Swedish Orphan Biovitrum's sustainability data and climate commitments